Abstract 7-Ethyl-10-hydroxycamptothecin (SN-38) loaded poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Pluronic F-108) and poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) nanoparticles were successfully prepared by a modified film hydration method and characterized by scanning electric microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM) and dynamic light scattering (DLS). Satisfactory drug loading of 20.73 ± 0.66% and a high encapsulation efficiency of 83.83 ± 1.32% were achieved. The SN-38 nanoparticles (SN-38 NPs) can completely disperse into a phosphate buffered saline (PBS) medium to produce a clear aqueous suspension that remains stable for up to three days. Total drug releases were 67.91% and 91.09% after 24 h in a PBS or fetal bovine serum (FBS) medium. Half maximal inhibitory concentration (IC 50 ) tests of SN-38 and SN-38 NPs on A549 lung cells produced results of 200.0 ± 14.9 ng ml −1 and 80.0 ± 4.6 ng ml −1 , respectively. Similarly, IC 50 tests of SN-38 and SN-38 NPs on MCF-7 breast cells yielded results of 16.0 ± 0.7 ng ml −1 and 8.0 ± 0.5 ng ml −1 , respectively. These in vitro IC 50 studies show significant (p < 0.01) enhancement of the SN-38 NP drug efficiency in killing cancer cells in comparison to the free drug SN-38 control. All the materials used for this nanoformulation are approved by the US FDA, with the virtue of extremely low toxicity to normal cells.
Introduction
7-Ethyl-10-hydroxycamptothecin (SN-38), derived from irinotecan hydrochloride (CPT-11) by carboxylesterases in the liver and in tumors, is a biologically active anticancer drug, which is effective against many malignancies including colorectal, lung, lymphoma, gastric, cervical, and ovarian cancer [1, 2] . SN-38 inhibits the release of single-strand DNA by forming a stable complex with topoisomerase I and DNA [3, 4] . SN-38 is approximately 1000 times more potent an inhibitor than CPT-11 [5] . However, its poor solubility in any pharmaceutically acceptable solvent and its pH sensitivity significantly limits its clinical applications. To improve the solubility and stability of SN-38, several nanocarriers have been investigated. Liposomes were commonly used to encapsulate SN-38 via a film hydration method and LE-SN-38 was developed by Zhang et al [2] . This liposome-based SN-38 drug was prepared in an alkaline environment with a pH of 10, in which SN-38 was soluble in its inactive carboxylate form. After lyophilization, LE-SN-38 was reconstituted at pH < 3 in order to transform the carboxylate form to active SN-38 and entrap the drug molecules inside a liposome bilayer. 2 mg ml −1 of LE-SN-38 was achieved and this formulation was used in clinical Phase I trials. Yasuyuki et al reported liposomalization of SN-38 using their modified remote loading method and achieved encapsulation rates of up to 53.0% [6] . Furthermore, it has been demonstrated that PEGylated liposomes can encapsulate SN-38 to achieve 9.51 ± 4.31% drug loading and 85 ± 1.21% encapsulation efficacy [7] . Copolymer methods also have great potential for nanocarriers of SN-38. NK012 was synthesized from poly(ethylene glycol)-block-poly(glutamic acid) and SN-38 and contained 20% (w/w) of SN-38 in copolymeric micelles [8, 9] . Poly(lactide-co-glycolide)-block-poly(ethylene glycol) conjugated with folic acid has a targeting function, can encapsulate SN-38, and attained 89.12 ± 9.2% encapsulation efficiency [10] . Complexes of SN-38 and PAMAM dendrimers are another nanocarrier option and have shown promise in oral drug delivery to minimize gastrointestinal toxicity. In addition, these complexes have high SN-38 solubility in aqueous media [11] [12] [13] .
In the work presented herein, Pluronic F-108 and PEG-b-PCL were used as an SN-38 nanocarrier. We chose these copolymers as a nanocarrier for several reasons. First, Pluronic F-108 and PEG-b-PCL are amphiphilic synthetic polymers containing hydrophilic poly(ethylene glycol) (PEG) blocks and hydrophobic poly(propylene glycol) (PPG) or poly(caprolactone) blocks. Pluronic F-108 was arranged in a triblock structure containing 82.5% PEG such that it was soluble in aqueous media. The PEG-b-PCL employed here was a diblock polymer with a molar weight of 10 kDa, which equaled the average molar weight of PEG and PCL. The PEG-b-PCL could only form a cloud while in aqueous solution. By combining PEG-b-PCL with Pluronic F-108, the final SN-38 NP solution was water soluble. Furthermore, the PCL segment was less water soluble than PPG, and thus PCL could incorporate more lipophilic drugs and could still finally form water-soluble micelles in aqueous medium with the assistance of the PEG segment. The hydrophilic PEG corona of the micelles prevented micelle aggregation and adsorption by proteins, and concealed the micelles from recognition by the reticuloendothelial system (RES) [14, 15] . Second, Pluronic copolymers and PEG-b-PCL possess low cytotoxicity for systemic administration. For instance, PEG-b-PCL is considered a biodegradable biomaterial. The molecular weight of Pluronic F-108 is 14.6 kDa, which is filtered easily by the kidneys and cleared through urine [16] . Third, the terminal hydroxyl groups of Pluronic F-108 shown in figure 1 were easy to modify to enhance their active tumor targeting ability for in vivo applications. In this paper, a mixture of Pluronic F108/PEG-b-PCL was used to load SN-38 to form SN-38 nanoparticles (SN-38 NPs). These copolymers greatly improve SN-38 loading, with a loading efficiency of 20.73 ± 0.66% and a drug encapsulation efficiency of 83.83 ± 1.32%. The schematic diagram of drug formulation is shown in figure 1 . Overall, SN-38 NPs became water soluble while the original chemical structure of the SN-38 remained unchanged. Our in vitro tests showed that SN-38 NPs achieved better biodistribution, thereby resulting in enhanced cancer killing.
Materials and methods

Materials
7-Ethyl-10-hydroxycamptothecin (≥98% (HPLC), powder), poly(ethylene glycol)-block-poly(caprolactone) methyl ether (poly(ethylene glycol) (PEG), average M n ∼5000 Daltons; polycaprolactone (PCL), average M n ∼5000 Daltons), poly(ethylene glycol)-block-poly(propylene glycol)-blockpoly(ethylene glycol) (Pluronic F-108, average M n ∼14 600 Daltons), 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), fluorescein isothiocyanate (FITC) and oleylamine were purchased from Sigma Aldrich, USA. Fisherbrand regenerated cellulose dialysis tubing (MWCO, 3500 Daltons) was obtained from Fisher Scientific, Canada. All other solvents were analytical or chromatographic grade.
Preparation of SN-38 NPs
SN-38-loaded micelles of Pluronic F-108 and PEG-b-PCL were prepared through a modified thin-film hydration method [17] . Briefly, SN-38 was dissolved in ethanol using ultrasound at room temperature, Pluronic F-108 was dissolved in ethanol using a vortex mixer, and PEG-b-PCL was dissolved in ethanol at 60 • C. These ethanol solutions were mixed at 60 • C in a 50 ml round-bottom flask using a digital vortex mixer at 3000 rpm for 2 min. The mixture was evaporated via rotary vacuum evaporation for about 30 min at 60 • C to remove the solvent and obtain a solid SN-38/copolymer film. This thin film was then hydrated with a pre-determined amount of PBS at room temperature, and the mixture was stirred using a digital vortex mixer at 3000 rpm for 2 min and sonicated to obtain a micelle solution, which was then centrifuged at 11 180g (10 000 rpm) for 10 min at room temperature to remove the unincorporated drug aggregate. Finally, the mixture was frozen at −78 • C for 2 h and dried (Freezone 4.5, Labconco) for 48 h. The content of SN-38 was measured by HPLC assay after disruption of SN-38 NPs dissolved in acetonitrile.
HPLC analysis
HPLC (1200 series, Agilent, USA) was used to analyze the drug loading and encapsulation efficiency of SN-38 NPs [18, 19] . The HPLC system used in these experiments has a UV detector at the wavelength of 265 nm. A reversed-phase column (Eclipse XDB-C18, 150 mm × 4.6 mm, 5 µm, C18 from Agilent, USA) was used at 30 • C. The mobile phase, consisting of acetonitrile and 25 mM NaH 2 PO 4 -H 3 PO 4 buffer (60 : 40, v/v), was freshly prepared for each run and degassed before use. A volume of 20 µl of sample solution was injected with a flow rate of 0.5 ml min −1 for the mobile phase. The typical retention time was around 3.0 min. Concentrations of SN-38 were determined by comparing the peak areas with the standard curve. The lyophilized SN-38 NPs were dissolved in acetonitrile (an effective solvent for SN-38), stirred at 3000 rpm by a digital vortex mixer for 2 min, and centrifuged at 161g (1200 rpm) for 5 min, and then the supernatant fraction was injected into the HPLC system.
Characterization of SN-38 NPs
Morphology of the SN-38 NPs was examined by scanning electron microscopy (SEM, Philips, XL 30), transmission electron microscopy (TEM, JEOL) and atomic force microscopy (AFM, Veeco). Mean size and distribution were measured by dynamic light scattering (DLS, Malvern, Zetasizer Nano S). The following is the sample preparation protocol.
(1) SEM samples. One drop of 1.0 mg ml −1 sonicated solution of SN-38 NPs was deposited on the surface of a clean silicon wafer. The silicon plate was dried by vacuum in a dark environment at room temperature for 2 h, then coated with a layer of gold for SEM viewing. (2) TEM samples. One drop of 1.0 mg ml −1 sonicated solution of SN-38 NPs was deposited on the surface of copper grids. The grids were air-dried in a dark environment at room temperature for 24 h, then negatively stained using 2% phosphotungstic acid for measurement via TEM.
(3) AFM samples. One drop of 2.0 mg ml −1 sonicated solution of SN-38 NPs was deposited on the surface of a clean silicon wafer. The silicon plate was dried by vacuum in a dark environment at room temperature for 2 h, then coated with a layer of gold for AFM viewing. (4) DLS sample. 1 ml of 1.0 mg ml −1 sonicated solution of SN-38 NPs was transferred into a small cuvette for DLS measurement.
Stability measurements
SN-38 easily hydrolyzes in an aqueous medium of pH > 7.
When SN-38 is sandwiched by copolymers, this will reduce the risk of SN-38 hydrolysis, but a trace amount of water inevitably exists inside of micelles and possibly hydrolyzes SN-38. Changes in SN-38 concentration could be evaluated as SN-38 stability in copolymeric micelles. SN-38 NPs were dispersed in PBS using a digital vortex mixer and sonication. Samples with 0.15 mg ml −1 of SN-38 were kept at in a dark environment at room temperature in preparation for HPLC testing.
During storage of SN-38 NP samples, the nanoparticles could aggregate and precipitate due to their interactions. The mean size and optical density (OD) [20] of the nanoparticles were used to monitor the physical stability of nanoparticles in solution. Briefly, 1 ml of SN-38 NPs in PBS medium was transferred into a small cuvette in order to determine the mean size of nanoparticles by dynamic light scattering (DLS, Malvern, Zetasizer Nano S); 3 ml of SN-38 NPs in PBS medium was transferred into a small cuvette and the optical density for spectroscopic absorbance at 650 nm was measured using a UV-visible spectrophotometer (Evolution 60, Thermo Scientific). Samples were kept in a dark environment at room temperature and sealed by film during successive measurements.
SN-38 release from SN-38 NPs
1 ml of SN-38 NP solution in phosphate buffered saline (PBS, Invitrogen TM , GIBCO) or fetal bovine serum (FBS, Invitrogen TM , GIBCO) with 100 µg ml −1 SN-38 was placed into a dialysis membrane and immersed in 50 ml of 1.0% Triton X-100 PBS solution. The system was shaken at 100 rpm (VWR TM , standard analog shaker) and 37 • C. At pre-determined intervals (2, 4, 6, 8 and 24 h), 0.5 ml of PBS solution with SN-38 was withdrawn and replaced with the same amount of fresh PBS medium. The previously mentioned 0.5 ml sample was mixed with 1.0 ml acetonitrile and adjusted by phosphoric acid to a pH of 3.0 for HPLC analysis.
In vitro cytotoxicity test of SN-38 NPs using MTT assay
Cell viability was evaluated using the MTT assay. MCF-7 cells were cultured in RPMI 1640 medium (Invitrogen TM , GIBCO) supplemented by 10% (v/v) FBS (1% w/v) penicillin-streptomycin at 37 • C in a humidified atmosphere of 5% CO 2 and 95% air. A549 cells were cultured in DMEM medium (Invitrogen TM , GIBCO) supplemented by 10% (v/v) FBS (1% w/v) penicillin-streptomycin at 37 • C in a humidified atmosphere of 5% CO 2 and 95% air. 200 µl of a 25 000 cells ml −1 suspension was seeded into each well of a 96-well plate and incubated overnight. 200 µl of fresh medium containing either drug (SN-38 in ethanol, SN-38 NPs in medium) or vehicle (ethanol) and carriers (PEG-b-PCL plus Pluronic F-108) were added to each well of the 96-well plate after removing the old medium. Cells were cultured for 72 h in an incubator, and the medium was then discarded. 180 µl of fresh medium and 20 µl of MTT were added to each well followed by incubation for 3 h. The old medium was again removed and each well was sufficiently dried before further measurements proceeded. 200 µl of DMSO was added to dissolve the MTT. The solution was agitated gently for 10 min, then measured for spectroscopic absorbance at 550 nm using a UV-visible spectrophotometer.
2.8. Cellular uptake studies 2.8.1. Cellular uptake by HPLC. Cellular uptake [16] was traced by HPLC. Six-well plates were seeded with MCF-7 or A549 cells at 2 ml of 300 000 cells per well, and the cells were allowed to attach for 24 h. The cells were then exposed to the medium only, SN-38 and SN-38 NP solutions at an SN-38 concentration of 10µg ml −1 at 37 • C. At pre-determined time intervals, the cells were washed three times with ice-cold PBS to terminate the uptake and remove the SN-38 and SN-38-loaded polymeric micelles that were adsorbed on cell membranes. Following this, the cells were lysed with 0.4 ml PBS containing 1% Triton X-100 and phosphoric acid (pH = 3.0). After a 30 min incubation, 200 µl of cell lysate was withdrawn and extracted with 400 µl acetonitrile, and the mixture was subjected to ultrasonic treatment (239 W, FS30H) in an ice bath for further SN-38 extraction. The extracts were centrifuged at 6000g (7300 rpm) for 6 min and the supernatants were subjected to HPLC analysis.
Fluorescent SN-38 NP preparation.
Preparation of fluorescent SN-38 NPs: FITC-polyaimde was synthesized and used as a water-insoluble FITC (in-FITC) [21] . Fluorescent SN-38 NPs were prepared using a thin-film hydration method. Briefly, in-FITC, SN-38 and copolymers were dissolved in ethanol and mixed in a 50 ml round-bottom flask using a digital vortex mixer at 3000 rpm for 2 min. The solvent was removed by rotary evaporation at 60 • C for about 30 min to obtain a solid in-FITC-SN-38/matrix. The resultant thin film was then hydrated with a pre-determined amount of water. The mixture was stirred using a digital vortex mixer at 3000 rpm for 2 min, then sonicated for 5 min to obtain a micelle solution, which was subsequently centrifuged at 11 180g (10 000 rpm) for 10 min at room temperature to remove unincorporated drug aggregates, followed by lyophilization (Freezone 4.5, Labconco) for 48 h.
Cellular fluorescent detection by FACS.
Six-well plates were seeded with MCF-7 cells at 300 000 cells per well in 2 ml, and the cells were allowed to attach for 24 h. Then cells were exposed to 2 ml of medium only and 2 ml of fluorescent SN-38 NP solutions with an SN-38 concentration of 500 ng ml −1 at 37 • C. After roughly 2-4 h, the cells were washed three times with ice-cold PBS to terminate the uptake and remove fluorescent SN-38-loaded polymeric micelles that were adsorbed on the cell membranes. 0.5 ml of trypsin was used to detach cells from the well and 3 ml of fresh medium was used to neutralize the trypsin. The samples were centrifuged at 252g (1500 rpm) for 10 min. The medium was subsequently removed and 0.5 ml of cold PBS was added for FACS (fluorescence activated cell sorting) detection (Becton Dickinson).
Cellular confocal microscopy.
MCF-7 or A549 cells were seeded on cover slips previously coated with poly-L-lysine (10 µg ml −1 ) for 45 min at 37 • C in a humidified atmosphere of 5% CO 2 and 95% air. The cell density was 1.5 × 105 cells cm −2 . The cells were exposed to 500 ng ml −1 fluorescent SN-38 NPs, with non-fluorescent SN-38 NPs used as a control. The cells were washed twice at pre-determined times with ice-cold PBS. After a 1-4 h incubation, the cells were fixed in 3.7% paraformaldehyde overnight at 4 • C, then cell membranes were stained with rhodamine phalloidin (Molecular Probes R , Invitrogen) for 1 h and the cell's nuclei were stained with DAPI, which was included in the mounting medium (Vectashield R H-1200, VECTOR) and measured by an inverted confocal laser scanning microscope (Carl Zeiss LSM510, Canada) equipped with imaging software (LSM 5 image browser, Carl Zeiss).
Statistical analysis
Experimental values were determined in three replicas. All values regarding measurement were expressed as means and standard deviations (SD). The one-way analysis of variance (ANOVA) and Tukey multiple comparison post-test were used. Differences less than 0.05 (p < 0.05) after correction were considered statistically significant.
Results and discussion
Preparation of SN-38 NPs
The thin-film hydration method was used to prepare SN-38 NPs. SN-38 can be dissolved completely in ethanol under sonication. The peak solubility of SN-38 is about 0.15 mg ml −1 in ethanol. Pluronic F-108 can also be thoroughly dissolved in ethanol at room temperature. PEGb-PCL cannot dissolve in ethanol at room temperature. It can be mixed with ethanol to yield a clear homogeneous solution at 60 • C. These three ethanol solutions were mixed and to achieve a clear drug and copolymer mixture at 60 • C. After the ethanol was removed from the mixture of SN-38 and copolymers, the matrix was added to PBS medium at room temperature. This drug copolymeric solution was stirred using a vortex mixer for two minutes and sonicated in an ultrasonic bath at room temperature, resulting in self-assembly formation of SN-38 entrapped copolymeric nanoparticles (SN-38 NPs). Since the Pluronic F-108 and PEG-b-PCL copolymers are amphiphilic block copolymers with PEG as a hydrophilic block and PPG or PCL as hydrophobic blocks, the formed SN-38 NPs may have a core-shell structure with hydrophobic PPG as the core entrapping precipitated SN-38, and PEG blocks as the hydrophilic stabilization shell. The drug loading content (DL) and the encapsulation efficiency (EE) were calculated by the following equations: DL% = mass of drug in micelles/total mass of drug and excipients × 100. EE% = mass of the drug in micelles/total mass of drug fed × 100.
Figure 2(a) shows that the ratio of PEG-b-PCL and Pluronic F-108 is very important in achieving a higher encapsulation efficiency of SN-38. When PEG-b-PCL contains 40% in the copolymers and the feeding ratio is 4:1, encapsulation efficiency is 92.17 ± 1.26%. If PEG-b-PCL or Pluronic F-108 is only used to arrest SN-38, encapsulation efficiency is low, only 3.8 ± 0.3% and 16.64 ± 0.1%, respectively. The reason why the encapsulation efficiency is sensitive to the ratio of PEG-b-PCL and Pluronic F-108 is that PEG-b-PCL and Pluronic F-108 have different hydrophilic-lipophilic balance (HLB) numbers. According to Griffin's formula [22, 23] , the expression pertaining to PEG-b-PCL HLB numbers is 20 × W PEG /W copolymer . Here W PEG is the weight of the hydrophilic portion and W copolymer is the weight of main chain polymer. The HLB number of PEG-b-PCL can be determined to be approximately 10. So PEG-b-PCL could easily encapsulate the insoluble SN-38 drug. When PEG-b-PCL with SN-38 or without SN-38 is put into water, it can only form a cloud solution. Pluronic F-108 with large amounts of PEG has an HLB number of 27 [24] , so it is too soluble in aqueous medium to catch SN-38 and can only force it into polymeric micelles with difficulty. When these two copolymers are mixed as a micelle system, the characteristics of PEG-b-PCL assist in the acquisition of SN-38 and Pluronic F-108 helps the micelles be compatible with the aqueous medium. Figure 2(b) shows that a high feeding ratio reduces encapsulation efficiency and increases drug loading. When feeding ratios are 4:1, 3:1 and 2:1, drug loading is 18.37%, 20.73% and 22.08% respectively, and encapsulation efficiency is 92.17%, 83.83% and 66.24% respectively. Therefore, when the feeding ratio is more than 3:1, encapsulation efficiency is significantly decreased and drug loading is slightly increased. Higher encapsulation efficiency and drug loading were achieved through optimizing the ratio of copolymers to that of the drug. The drug loading rate was found to be 20.73 ± 0.66%, with an encapsulation efficiency of 83.83 ± 1.32%. Figure 2(c) shows that the mean size of SN-38 NPs in aqueous medium slightly increased with feeding ratio. This might be caused by more drugs in the micelles when the feeding ratio is increased.
Morphology and size of SN-38 NPs
The morphological structure of SN-38 NPs was characterized by SEM, TEM and AFM. The SEM, TEM, and AFM pictures are shown in figure 3 , which indicate that the majority of the SN-38 NPs are spherical. Figure 3(b) shows the core-shell structure of the SN-38 NPs with hydrophobic PPG as the core entrapping the precipitated SN-38, and the PEG block as the hydrophilic stabilization shell. Figure 3(c) shows SN-38 NP aggregation during the drying process. This implies that the SN-38 NP solution could lose its stability if the concentration of SN-38 NPs becomes too high. The SN-38 NPs were determined by DLS measurements to have a mean diameter of approximately 128.3 nm in figure 3(d) . Figure 4 shows that SN-38 could be hydrolyzed in an aqueous environment, especially in an aqueous solution with pH > 7 [25] . It is important to avoid hydrolysis of SN-38 and keep the SN-38 in its original form while performing the SN-38 formulation. Following this, copolymers are dissolved in water to form core-shell structure micelles. Note that the inside of core-shell micelles could potentially contain some water. Water content is related to the critical micelle concentration (CMC). Normally, the smaller the CMC of copolymers, the less water is expected to be found in the resultant micelles. When SN-38 is encapsulated by copolymers with low CMC, it has a reduced probability of coming into contact with water. In turn, its degree of degradation is lower than the drug alone. The SN-38 concentration in copolymeric solution could be used to evaluate the stability of SN-38 NPs in solution. SN-38 concentration in an SN-38 NP solution was determined by HPLC. Figure 5(a) shows SN-38 in an SN-38 NP solution of 0.15 mg ml −1 ; SN-38 lost less than 6% of the originally encapsulated drug over a period of three days. Hence, the mixed micelles were very efficient at retaining their encapsulated drug load. As presented in figure 5(b) , the mean size of SN-38 NPs was increased from 128.3 to 133.0 nm after three days of settling. This might be due to the slight aggregation of nanoparticles within this period of time. Optical density, which makes use of a spectroscopic absorbance at 650 nm, is proportional to the degree of turbidity in the SN-38 NP solution. Changes in optical density indicate the gathering of nanoparticles and precipitation because of drug release from mixed micelles or broken copolymer micelles. Figure 5(b) shows that the turbidity of SN-38 NP solution increased slightly, yet still remained at a low optical density after three days. Figure 6 shows the cumulative release profiles up to 24 h for SN-38 NPs in PBS and FBS media at 37 • C. SN-38 in SN-38 NP solutions was dialyzed into a 0.1% Triton X-100 PBS medium. We found the released medium cloudy, and thus SN-38 in PBS with 0.1% Triton X-100 could not be properly traced by HPLC. It is theorized that SN-38 was hydrolyzed following its release into a PBS medium with a pH of 7.4. Therefore, a released sample was used to adjust the pH of the medium to 3.0 using phosphoric acid, and Triton X-100 concentration was increased from 0.1 to 1%. SN-38 concentration was tracked by HPLC at 3.0 min of retention time. Total SN-38 NP release in PBS and FBS was 67.91% and 91.09% after 24 h, respectively. Note that the SN-38 released from the SN-38 NPs in the FBS medium tests was more than that of the PBS medium. We also found that SN-38 concentration was significantly reduced for time periods greater than the initial 24 h of release. This implies that the degradation of SN-38 in an aqueous medium is substantial. The graphs presented in this study only detail the concentration of SN-38 up to the designated release time limit of 24 h. To trace cellular uptake of SN-38 NPs with time, fluorescent SN-38 NPs were synthesized by the thin-film hydration method. The fluorescent SN-38 NPs contain the SN-38 drug, in-FITC Pluronic F-108 and PEG-b-PCL, where the in-FITC and SN-38 are located inside the copolymeric micelles. When these micelles went into cells, the cells could only take up whole micelles, not each ingredient separately. Therefore, the intensity of cell fluorescence reflected SN-38 drug uptake. Figure 8 shows how the intensity of cells became stronger as time progressed, which indicates that cells absorbed more drug nanoparticles as more time elapsed.
Stability of SN-38 NPs
SN-38 release from SN-38 NPs
To gain a clear idea of the cellular uptake of SN-38 NPs located inside of cells or on the surface of the cell membrane, fluorescent SN-38 NPs were used to study the uptake of SN-38 NPs on MCF-7 or A549 cancer cells. Compared to the control, figure 9 shows cellular uptake of the original SN-38 and SN-38 NPs after 2 or 4 h have elapsed. Note that a stronger green signal indicates that more of the drug is entering the cells as time progresses.
Conclusion
In this study, a new nanoformulation of SN-38 nanoparticles was successfully developed. The SN-38 NPs are superior to the original SN-38 drug for a variety of reasons. First, the SN-38 nanoformulation imparted water solubility without changing the drug's chemical structure, with a peak solubility of 0.15 mg ml −1 of SN-38 in an aqueous medium. Second, the nanoformulation displayed a great drug loading of 20%, while still maintaining a respectable encapsulation efficiency of 83%. It should be noted that this increased drug loading will have a direct impact on negative side effects for potential patients making use of the nanoformulation. Third, SN-38 NPs combine multiple functions, most notably imaging and cancer killing. In addition to sensing and treating functions, the ingredients in the nanoformulation, such as PEG, also assist SN-38 in evading filtration via the reticuloendothelial system, thereby prolonging circulation half-life. Finally, we can label SN-38 with fluorescent tags for tracking the drug for diagnosis and targeted delivery. We developed a new nanoformulation for SN-38 that used two different types of copolymer to significantly enhance the capability of SN-38 drug loading up to a peak value of 20%. The SN-38 NPs showed greater drug efficacy in cancer cells. These results open up further exploration of biomedical applications of novel SN-38 NPs for potential clinical applications in the future. One important advantage of these nanoparticles is their potential to combine multiple functional groups, such as targeting ligands, other drugs, and multiple molecules, into a single platform to achieve synergistic effects. The use of targeting ligands on SN-38 NPs for tumor-targeted drug delivery is also expected to further enhance treatment efficacy. Overall, the reported nanoformulation may help SN-38 achieve a personalizable, image-guided cancer therapy.
